Clinical trial · Observational
Prospective Observational Study of a Precision Medicine Approach in Patients With Advanced Cancer
NCT05926284CI-TRIAL-00067762PRIMErecruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Prospective observational study of a precision medicine approach in patients with advanced cancer. In this registrational study, patients with advanced cancer undergoing extensive molecular sequencing within the precision oncology program of Charité University Medicine, Berlin will be registered and followed to assess the efficacy of the program and assess the clinical relevance and frequency of molecular alterations, individualized therapies and novel molecular analysis tools.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (2)
- measure
- Frequency of personalized treatment initiation
- timeFrame
- At 1 year from date of study inclusion
- description
- Frequency of personalized treatment initiation
- measure
- Frequency of molecularly stratified treatment options
- timeFrame
- At 1 year from date of study inclusion
- description
- Number of molecularly stratified treatment options per patient
Secondary outcomes (10)
- measure
- Progression free survival
- timeFrame
- Assessed up to 100 months
- description
- From date of study inclusion until the date of first documented progression or date of death from any cause, whichever came first
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * advanced cancer * ability to give written informed consent * performance status allows initiation of a potential targeted treatment after molecular analysis * molecular analysis has been done or planned Exclusion Criteria: \- unable to give written informed consent
References
Publications (0)
Data not yet available
No reference posted for this study.